Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
87322 trials found · Page 104 of 4367
-
Engineered immune cells battle tough lymphoma in early trial
Disease control CompletedIn this single-center, open-label, no control, prospective clinical trial, a total of 10 relapsed or refractory CD19 positive B-cell Non-Hodgkin Lymphoma (NHL) patients will be enrolled.CD19 CAR T cells(total dose of 2×10\^6/kg-1×10\^7/kg) will be intravenously infused to patient…
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Apr 22, 2026 15:58 UTC
-
Engineered immune cells show promise against stubborn lymphoma
Disease control CompletedThe goal of this study is to assess whether axicabtagene ciloleucel improves the clinical outcome in participants with relapsed or refractory indolent non-Hodgkin lymphoma (r/r) iNHL.
Phase: PHASE2 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Apr 29, 2026 01:35 UTC
-
New drug cocktail shows promise in slowing lung cancer
Disease control OngoingThis is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy + Standard of care (SoC) chemotherapy or durvalumab monotherapy + SoC chemotherapy versus SoC chemotherapy alone as first …
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 26, 2026 19:36 UTC
-
Immunotherapy shows promise in lung cancer battle
Disease control CompletedThe primary objectives of the study are: * To compare the overall survival (OS) of cemiplimab versus standard-of-care platinum-based chemotherapies in the first-line treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 i…
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Apr 29, 2026 01:36 UTC
-
New hope for older AML patients: targeted pill plus low-dose chemo extends survival
Disease control CompletedThe primary objective of this study is to evaluate if venetoclax when co administered with low-dose cytarabine (LDAC) improves overall survival (OS) versus LDAC and placebo, in treatment-naïve patients with acute myeloid leukemia (AML).
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Apr 29, 2026 01:34 UTC
-
Targeted pill tested for Hard-to-Treat cancers driven by RET gene
Disease control OngoingThis is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants with advanced solid tumors, including rearranged duri…
Phase: PHASE1, PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Apr 13, 2026 20:18 UTC
-
Cold sore virus weaponized to fight breast cancer
Disease control CompletedThe purpose of this study is to determine if an oncolytic virus called Talimogene laherparepvec (a modified herpes simplex 1 virus that can specifically destroy cancer cells while leaving normal cells alone) injected directly into the tumor during chemotherapy prior to surgery ca…
Phase: PHASE1, PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Apr 13, 2026 20:17 UTC
-
Major trial tests drug to stop kidney cancer from coming back after surgery
Disease control OngoingThis phase III trial compares nephrectomy (surgery to remove a kidney or part of a kidney) with nivolumab to the usual approach of nephrectomy followed by standard post-operative follow-up and monitoring, in treating patients with kidney cancer that is limited to a certain part o…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 22, 2026 15:58 UTC
-
New hope for liver cancer patients after first treatment fails
Disease control CompletedThe purpose of this study is to determine the efficacy and safety of pembrolizumab or placebo given with best supportive care (BSC) in Asian participants with previously systemically treated advanced hepatocellular carcinoma (HCC). The primary hypothesis of this study is that ove…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Apr 15, 2026 16:14 UTC
-
New lung cancer pill shows promise in slowing tumor growth
Disease control OngoingA phase 3 study to demonstrate whether lorlatinib given as monotherapy is superior to crizotinib alone in prolonging the progression-free survival in advanced ALK-positive NSCLC patients who are treatment naïve and to compare lorlatinib to crizotinib with respect to overall survi…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 29, 2026 01:35 UTC
-
Radiation boost could help rectal cancer patients skip major surgery
Disease control Recruiting nowA randomized study of 131 patients. Patients with a clinical T2-3 N0 rectal cancer will be randomized to two arms (arm A: standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy compared to arm B: standard chemoradiati…
Phase: PHASE2, PHASE3 • Sponsor: Sir Mortimer B. Davis - Jewish General Hospital • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Scientists re-engineer Patients' own cells to hunt down multiple cancers
Disease control Recruiting nowBackground: In a new cancer therapy, researchers take a person s blood, select a certain white blood cell to grow in the lab, and then change the genes of these cells using a virus. The cells are then given back to the person. This is called gene transfer. For this study, resear…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 20, 2026 16:18 UTC
-
Immunotherapy combo fights advanced head and neck cancer
Disease control CompletedThe purpose of this study is to determine the efficacy and safety of pembrolizumab given concomitantly with chemoradiation (CRT) and as maintenance therapy versus placebo plus CRT in participants with locally advanced head and neck squamous cell carcinoma (LA HNSCC). The primary …
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Apr 13, 2026 20:21 UTC
-
Scientists test Cancer-Killing virus in patients with aggressive blood cancers
Disease control Recruiting nowThis phase I trial studies the best dose and side effects of the VSV-hIFNβ-NIS vaccine with or without cyclophosphamide and combinations of ipilimumab, nivolumab, and cemiplimab in treating patients with multiple myeloma, acute myeloid leukemia or lymphoma that has come back afte…
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Apr 07, 2026 14:36 UTC
-
Precision medicine aims to boost cure rates for kids with blood cancers
Disease control OngoingThe overarching objective of this study is to use novel precision medicine strategies based on inherited and acquired leukemia-specific genomic features and targeted treatment approaches to improve the cure rate and quality of life of children with acute lymphoblastic leukemia (A…
Phase: PHASE2, PHASE3 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Apr 26, 2026 19:38 UTC
-
New drug combo shows promise for tough lung cancer
Disease control OngoingThis is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of combining durvalumab ± tremelimumab with platinum based chemotherapy (EP) followed by durvalumab ± tremelimumab maintenance therapy versus EP alone as first-line treatme…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 24, 2026 16:18 UTC
-
New immune therapy combo tested in fight against spreading prostate cancer
Disease control CompletedThe purpose of this study is to evaluate the effectiveness, safety and tolerability of nivolumab followed by ipilimumab, in subjects with metastatic castration resistant prostate cancer (mCRPC).
Phase: PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Apr 09, 2026 19:32 UTC
-
Immunotherapy duo shows promise against tough bladder cancer
Disease control OngoingThe purpose of this study is to determine whether an investigational immunotherapy nivolumab in combination with ipilimumab or in combination with standard of care chemotherapy is more effective than standard of care chemotherapy alone in treating participants with previously unt…
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Apr 23, 2026 12:45 UTC
-
Half-Match transplant offers hope for sickle cell patients without full sibling donors
Disease control Recruiting nowThe study is a Phase II clinical trial. Patients will receive intensity modulated total body irradiation (TBI) at a dose of 3 Gy with standard fludarabine/ i.v. cyclophosphamide conditioning prior to human leukocyte antigen (HLA)-haploidentical hematopoietic stem cell transplant …
Phase: PHASE2 • Sponsor: University of Illinois at Chicago • Aim: Disease control
Last updated Apr 13, 2026 20:19 UTC
-
New hope for kids: gentler transplant could control devastating blood diseases
Disease control Recruiting nowThis study is designed to estimate the efficacy and toxicity of familial HLA mismatched bone marrow transplants in patients with non-malignant disease who are less than 21 years of age and could benefit from the procedure.
Phase: PHASE1, PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Apr 17, 2026 16:11 UTC